G1 Therapeutics Inc (NASDAQ:GTHX) CFO Barclay A. Phillips sold 5,000 shares of the business’s stock in a transaction on Thursday, November 15th. The stock was sold at an average price of $39.92, for a total transaction of $199,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

NASDAQ GTHX opened at $41.35 on Monday. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of -11.58 and a beta of 1.16. G1 Therapeutics Inc has a 52 week low of $18.03 and a 52 week high of $69.57.

G1 Therapeutics (NASDAQ:GTHX) last posted its quarterly earnings data on Wednesday, November 7th. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.67) by $0.08. As a group, equities analysts anticipate that G1 Therapeutics Inc will post -2.49 EPS for the current fiscal year.

Several brokerages recently weighed in on GTHX. JPMorgan Chase & Co. boosted their price target on shares of G1 Therapeutics from $58.00 to $63.00 and gave the stock an “overweight” rating in a research report on Friday, August 10th. Needham & Company LLC dropped their price objective on shares of G1 Therapeutics from $76.00 to $74.00 and set a “buy” rating for the company in a research note on Thursday, November 8th. BTIG Research began coverage on shares of G1 Therapeutics in a research note on Monday, September 10th. They set a “buy” rating and a $80.00 price objective for the company. BidaskClub lowered shares of G1 Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, October 25th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $79.00 price objective on shares of G1 Therapeutics in a research note on Monday, September 17th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. G1 Therapeutics presently has an average rating of “Buy” and an average target price of $74.00.

A number of hedge funds and other institutional investors have recently bought and sold shares of GTHX. State Board of Administration of Florida Retirement System boosted its stake in shares of G1 Therapeutics by 17.5% during the third quarter. State Board of Administration of Florida Retirement System now owns 8,581 shares of the company’s stock valued at $449,000 after purchasing an additional 1,280 shares during the period. Teachers Retirement System of The State of Kentucky boosted its stake in shares of G1 Therapeutics by 12.0% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 14,021 shares of the company’s stock valued at $733,000 after purchasing an additional 1,501 shares during the period. Great West Life Assurance Co. Can boosted its stake in shares of G1 Therapeutics by 148.3% during the second quarter. Great West Life Assurance Co. Can now owns 2,612 shares of the company’s stock valued at $113,000 after purchasing an additional 1,560 shares during the period. Swiss National Bank boosted its stake in shares of G1 Therapeutics by 4.5% during the third quarter. Swiss National Bank now owns 37,100 shares of the company’s stock valued at $1,940,000 after purchasing an additional 1,600 shares during the period. Finally, United Services Automobile Association boosted its stake in shares of G1 Therapeutics by 2.4% during the third quarter. United Services Automobile Association now owns 72,398 shares of the company’s stock valued at $3,786,000 after purchasing an additional 1,704 shares during the period. 64.04% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This piece was originally published by Daily Political and is the property of of Daily Political. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.dailypolitical.com/2018/11/19/g1-therapeutics-inc-gthx-cfo-barclay-a-phillips-sells-5000-shares.html.

About G1 Therapeutics

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.

Further Reading: What is Depreciation?

Insider Buying and Selling by Quarter for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.